NEW YORK, NY / ACCESSWIRE / September 19, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Tuya Inc. (NYSE:TUYA)
This lawsuit is on behalf of all persons or entities who purchased Tuya American Depositary Shares in or traceable to the Company's March 2021 initial public offering.
Lead Plaintiff Deadline: October 11, 2022
Learn about your recoverable losses in TUYA: https://www.kleinstocklaw.com/pslra-1/tuya-class-action-submission-form?id=31925&from=1
Co-Diagnostics, Inc. (NASDAQ:CODX)
This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m. ET).
Lead Plaintiff Deadline: October 17, 2022
The CODX lawsuit alleges Co-Diagnostics, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) demand for the Company's Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants' positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.
Learn about your recoverable losses in CODX: https://www.kleinstocklaw.com/pslra-1/co-dx-class-action-loss-submission-form?id=31925&from=1
Humanigen, Inc. (NASDAQ:HGEN)
Class Period: May 28, 2021 - July 12, 2022
Lead Plaintiff Deadline: October 25, 2022
The HGEN lawsuit alleges that throughout the class period, Humanigen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Humanigen's lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in HGEN: https://www.kleinstocklaw.com/pslra-1/humanigen-inc-class-action-loss-submission-form?id=31925&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: